Harvest One Phase II Clinical Trials on Satipharm CBD GelPell Published in Peer-Reviewed Medical Journal

VANCOUVER, Aug. 13, 2019 /PRNewswire/ – Harvest One Inc. (“Harvest One” or the “Company“) (TSXV: HVT; OTCQX: HRVOF), through its wholly-owned subsidiary Satipharm Ltd. (“Satipharm“), today announced positive results of a Phase 2 clinical trial of its CBD GelPell® capsules in the management of Treatment Resistant Epilepsy (TRE) have been published in Epilepsy Behaviour, a bimonthly peer-reviewed medical journal covering behavioral aspects of epilepsy.

Harvest One Cannabis Inc. (CNW Group/Harvest One Cannabis Inc.)

Highlights include;

by

Leave a Reply

Harvest One Phase II Clinical Trials on Satipharm CBD GelPell Published in Peer-Reviewed Medical Journal

VANCOUVER, Aug. 13, 2019 /PRNewswire/ – Harvest One Inc. (“Harvest One” or the “Company“) (TSXV: HVT; OTCQX: HRVOF), through its wholly-owned subsidiary Satipharm Ltd. (“Satipharm“), today announced positive results of a Phase 2 clinical trial of its CBD GelPell® capsules in the management of Treatment Resistant Epilepsy (TRE) have been published in Epilepsy Behaviour, a bimonthly peer-reviewed medical journal covering behavioral aspects of epilepsy.

Harvest One Cannabis Inc. (CNW Group/Harvest One Cannabis Inc.)

Highlights include;

by

Leave a Reply